Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Funding News

11/14/2024
AIDealsDiagnosticFundingGene TherapyGlaucomaNewsletterRetinaSurgical
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering

EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...

11/14/2024
CataractClinical TrialDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIndustryInstrumentsMicroscopesNewsletterOCTPresbyopiaRegulationRetinaStudySurgical
November 2024 Ophthalmic News Briefs
November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

11/1/2024
BreakingFundingPharmaRetina
RevOpsis Awarded $1.8 Million NEI Grant to Advance Retinal Candidate RO-104
RevOpsis Awarded $1.8 Million NEI Grant to Advance Retinal Candidate RO-104

RevOpsis Therapeutics announced Oct. 15 that it had been awarded a Small Business Innovation Research grant of $1.8 million from the National Eye Institute (NEI) to advance lead asset RO-104 for ex...

10/25/2024
BreakingDiagnosticDry EyeFundingStudy
ARPA-H Seeks Proposals for Tear Duct-Based Diagnostic System, Plus Custom Dosing Platform
ARPA-H Seeks Proposals for Tear Duct-Based Diagnostic System, Plus Custom Dosing Platform

ARPA-H announced Oct. 18 that it had launched a new program to develop a tear-based biomarker measurement system that can be inserted into the tear duct to provide continuous health monitoring, pai...

10/25/2024
BreakingCornealDealsDry EyeFundingStudy
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure

Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...

10/15/2024
AIDealsDiagnosticDigitalFundingMyopiaNewsletterPharmaPresbyopiaRetina
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing

Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...

10/15/2024
DealsESCRSEuropeFundingMeetingNewsletter
Investors Take Temperature of Ophthalmic Market at European Futures Forum
Investors Take Temperature of Ophthalmic Market at European Futures Forum

The 2024 Ophthalmology Futures European Forum reviewed the decline in ophthalmic deals in 2024 before offering presenting companies some guidance on how to advance their technology in such an envir...

10/4/2024
BreakingCataractFundingPharmaRegulation
Eyenovia Launches Clobetasol Drops for Postoperative Pain, Inflammation
Eyenovia Launches Clobetasol Drops for Postoperative Pain, Inflammation

Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...

10/4/2024
BreakingDealsFundingRetina
Boehringer Ingelheim to Advance Surrozen’s Bi-specific Antibody in Retinal Disease
Boehringer Ingelheim to Advance Surrozen’s Bi-specific Antibody in Retinal Disease

Surrozen announced Sept. 24 that development partner Boehringer Ingelheim will advance SZN-413, a bi-specific antibody targeting retinal vascular disease. The milestone triggers a $10 million payme...

9/19/2024
CataractFundingGene TherapyMyopiaNewsletterPharmaRetina
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round

ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...

8/21/2024
DiagnosticDry EyeFundingGene TherapyLaserNewsletterRetina
MeiraGTx Leads Latest Ophthalmic Fundraising with $50 Million Offering
MeiraGTx Leads Latest Ophthalmic Fundraising with $50 Million Offering

MeiraGTx led recent ophthalmic fundraising efforts with a $50 million offering of ordinary shares as it moves forward with its extensive pipeline of gene therapy candidates. Financing announced in ...

8/16/2024
BreakingFundingGene TherapyRegulationRetina
US FDA Approves Expanded Access Program for Ocugen’s RP Candidate
US FDA Approves Expanded Access Program for Ocugen’s RP Candidate

Ocugen announced Aug. 5 that the US FDA had approved an expanded access program to allow for the treatment of adults with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candi...

7/23/2024
AcquisitionsDealsFundingNewsletter
Q2-2024 Ophthalmic Deals Total More Than $1.6 Billion, Include One Strategic Purchase
Q2-2024 Ophthalmic Deals Total More Than $1.6 Billion, Include One Strategic Purchase

Ophthalmic deals in Q2-2024 reached over $1.6 billion and involved 19 transactions. This compares with $7.0 billion from 25 transactions in Q2-2023 and $2.0 billion from 17 transactions in Q1-2024....

7/23/2024
BiosimilarsCornealFundingGene TherapyMyopiaNewsletterPresbyopiaRetina
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B

Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...

7/5/2024
BreakingCornealDealsFundingRefractive
J&J Leads Series A Round for Crosslinking Tech Developer TecLens
J&J Leads Series A Round for Crosslinking Tech Developer TecLens

Johnson & Johnson is the lead investor in a Series A funding round for Stamford, Connecticut-based TecLens, developer of a new crosslinking technology, J&J announced June 21. The technology is inte...

6/24/2024
DealsDiagnosticFundingGene TherapyGlaucomaNewsletterPharmaRetinaTelehealth
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer

Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...

6/14/2024
BreakingDeviceFundingProsthesisRetina
LambdaVision Reports First Closing of Seed Round to Advance Artificial Retina
LambdaVision Reports First Closing of Seed Round to Advance Artificial Retina

LambdaVision, of Farmington, Connecticut, reported May 29 that it had secured the first closing of a seed round, let by Aurelia Foundry Fund, a fund spun out of Massachusetts Institute of Technolog...

5/22/2024
AICataractDiagnosticFundingGene TherapyGlaucomaIOLNewsletterRetina
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering

RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...

4/24/2024
DealsFundingNewsletter
Retinal Pharmaceutical Transactions Drive Ophthalmic Deals in First Quarter of 2024
Retinal Pharmaceutical Transactions Drive Ophthalmic Deals in First Quarter of 2024

Ophthalmic deals in Q1-2024 reached over $2.1 billion and involved 20 transactions. This compares with $2.0 billion from 17 transactions in Q1-2023 and $570 million from 12 transactions in Q4-2023....

4/24/2024
AICataractCornealDiagnosticFundingGlaucomaIndiaLaserNewsletterPharmaRetina
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements

Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...

4/24/2024
Clinical TrialCornealData SecurityDealsDiagnosticDry EyeEnvironmentFundingGlaucomaIOLIndustryMicroscopesNewsletterRegulationRetina
April 2024 Ophthalmic News Briefs
April 2024 Ophthalmic News Briefs

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...

4/12/2024
BreakingEmergingEuropeFundingGlaucomaSurgical
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis

Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...

3/22/2024
BreakingFundingSurgical
Bascom Palmer Uses $1 Million Gift to Launch Whole Eye Transplant Initiative
Bascom Palmer Uses $1 Million Gift to Launch Whole Eye Transplant Initiative

Bascom Palmer Eye Institute reported March 5 that it would use a $1 million donation to fast-forward its initiative to transplant a whole eye. The hospital, part of the University of Miami, said th...

3/21/2024
DiagnosticFundingNewsletterOCT
Washington U. Gets up to $20M ARPA-H Grant to Create Portable OCT
Washington U. Gets up to $20M ARPA-H Grant to Create Portable OCT

Washington University in St. Louis, Missouri, announced Feb. 13 that one of its professors had been awarded a grant of up to $20 million from the Advanced Research Projects Agency for Health (ARPA-...

3/21/2024
DiagnosticDry EyeFundingNewsletterRetina
Ocular Tx Leads Latest Ophthalmic Fundraising with $325 Million Private Placement
Ocular Tx Leads Latest Ophthalmic Fundraising with $325 Million Private Placement

Ocular Therapeutix led recent ophthalmic fundraising efforts with a $325 million private placement to advance its candidate for wet age-related macular degeneration. Financing announced in the past...

3/8/2024
BreakingDry EyeFunding
Tarsus Prices $100 Million Public Offering
Tarsus Prices $100 Million Public Offering

Tarsus Pharmaceuticals, of Irvine, California, announced March 1 that it had priced an underwritten public offering of shares and warrants, with expected gross proceeds of $100 million. Goldman Sac...

2/23/2024
BreakingFundingIndustryRetina
Ocular Therapeutix Announces $325 Million Private Placement, Adds Retina Specialists to Leadership Team
Ocular Therapeutix Announces $325 Million Private Placement, Adds Retina Specialists to Leadership Team

Ocular Therapeutix announced Feb. 22 that it had entered into a securities purchase agreement with institutional investors for a private placement of shares, with gross proceeds of approximately $3...

2/23/2024
BreakingCornealFundingStudy
Australian Research Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea
Australian Research Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea

Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...

2/23/2024
BreakingDiagnosticFundingOCT
Washington U. Awarded up to $20 Million Federal Grant to Create Portable OCT
Washington U. Awarded up to $20 Million Federal Grant to Create Portable OCT

Washington University in St. Louis, Missouri, announced Feb. 13 that one of its professors had been awarded a grant of up to $20 million from the Advanced Research Projects Agency for Health (ARPA-...

2/22/2024
DealsFundingGene TherapyGlaucomaNewsletterRetinaSurgical
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering

4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...

2/22/2024
CornealFundingNewsletterStudy
Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea
Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea

Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...

2/9/2024
BreakingFundingGene TherapyRetina
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Trial for Wet AMD
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Trial for Wet AMD

4D Molecular Therapeutics reported Feb. 3 that it had seen positive topline results from the Phase II PRISM trial evaluating 4D-150, an intravitreal gene therapy candidate, in wet age-related macul...

2/2/2024
BreakingDealsFundingPharmaRetina
New Company Eyconis Formed to Develop Ascendis Pharma's Ophthalmology Assets
New Company Eyconis Formed to Develop Ascendis Pharma's Ophthalmology Assets

Denmark’s Ascendis Pharma announced Jan. 29 that it had founded Eyconis, a separate company to develop and commercialize its ophthalmic assets globally. The company is launching with a $150 million...

1/26/2024
BreakingFundingRegulationRetina
Outlook Confirms Protocol for New Trial of Ophthalmic Bevacizumab, Raises up to $172 Million in Private Placements
Outlook Confirms Protocol for New Trial of Ophthalmic Bevacizumab, Raises up to $172 Million in Private Placements

Outlook Therapeutics reported Jan. 23 that it had received written agreement from the US FDA confirming the protocol of a new clinical trial for ONS-5010, an ophthalmic formulation of bevacizumab, ...

1/26/2024
BiosimilarsBreakingFundingRegulationRetina
Xbrane Reports Plan to Raise Up to $40.2 Million to Launch Ranibizumab Biosimilar Ximluci
Xbrane Reports Plan to Raise Up to $40.2 Million to Launch Ranibizumab Biosimilar Ximluci

Swedish biosimilar drug developer Xbrane reported Jan. 22 a rights issue of units to raise SEK 343 million ($32.8 million, converted on Jan. 22, 2024) in funding. Xbrane said the offering primarily...

1/26/2024
BreakingFundingStudy
Two University of Colorado Ophthalmic Researchers Receive Accelerator Grants
Two University of Colorado Ophthalmic Researchers Receive Accelerator Grants

Two ophthalmic researchers at the University of Colorado’s Anschutz Medical Campus are among nine winners of grants from the Anschutz Acceleration Initiative, a UC Anschutz program that grants awar...

1/23/2024
DealsFundingNewsletter
Ophthalmology Sees Large Acquisitions in 2023; Dollar Total Reaches Three-Year High
Ophthalmology  Sees Large Acquisitions in 2023; Dollar Total Reaches Three-Year High

Ophthalmic deals in 2023 reached nearly $12.3 billion and included 78 transactions. This compares with $5.7 billion in 2022 and $8.5 billion in 2021. Mergers and acquisitions totaled $8.9 billion; ...

1/23/2024
FundingIndustryNewsletter
2023 in Review: SVB Failure Sparks Initial Panic in Ophthalmic Medtech Sector
2023 in Review: SVB Failure Sparks Initial Panic in Ophthalmic Medtech Sector

Silicon Valley Bank, of Santa Clara, California, was seized by the US government on March 11, 2023, in the second largest bank failure in US history. The failure caused a great deal of initial pani...

1/23/2024
CornealDry EyeFundingNewsletterPresbyopiaRetina
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round

China’s Ji Xing Pharmaceuticals led recent ophthalmic fundraising efforts with $162 million in Series D funding to advance its pipeline, which includes five ophthalmic candidates. Financing announc...

1/23/2024
FundingIndustryNewsletterRetina
Oxurion Avoids Bankruptcy, Will Focus on Preclinical Programs in GA
Oxurion Avoids Bankruptcy, Will Focus on Preclinical Programs in GA

Belgium’s Oxurion announced Dec. 28 that it had avoided bankruptcy through an agreement with its main creditor, Atlas Special Opportunities. Atlas will continue to fund Oxurion under an existing 20...

1/5/2024
BreakingDealsFundingIndustryRetina
Oxurion Avoids Bankruptcy, Will Focus on Preclinical Programs in GA
Oxurion Avoids Bankruptcy, Will Focus on Preclinical Programs in GA

Belgium’s Oxurion announced Dec. 28 that it had avoided bankruptcy through an agreement with its main creditor, Atlas Special Opportunities. Atlas will continue to fund Oxurion under an existing 20...

12/29/2023
BreakingCornealFundingIndustry
KeraLink International Launches Cornea Accelerator, Issues $100K Challenge to Innovators
KeraLink International Launches Cornea Accelerator, Issues $100K Challenge to Innovators

KeraLink International, a nonprofit group focused on eradicating global corneal blindness, announced Dec. 11 that it had launched a Cornea Technology Accelerator, open to entrepreneurs and innovato...

12/14/2023
DiagnosticFundingNewsletterRetina
EyePoint Leads Latest Ophthalmic Fundraising with $200 Million Public Offering
EyePoint Leads Latest Ophthalmic Fundraising with $200 Million Public Offering

EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $200 million upsized public offering, as it continues to advance its anti-VEGF implant for retinal disease. Financing annou...

11/21/2023
CornealDiagnosticDry EyeFundingGlaucomaNewsletterRetina
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A

EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...

11/10/2023
BreakingFundingGene TherapyIndustryRetina
Ascidian Raises $40 Million in Series A Funding, Appoints Michael Ehlers as Interim President, CEO
Ascidian Raises $40 Million in Series A Funding, Appoints Michael Ehlers as Interim President, CEO

Ascidian Therapeutics announced Nov. 8 that it had raised $40 million in Series A extension funding from life sciences venture capital company Apple Tree Partners. Ascidian, of Boston, Massachusett...

10/24/2023
FundingGene TherapyMeetingNewsletterRefractive
Futures Forums Cater to Companies that Can’t Gain Limelight Elsewhere, Co-founder Says
Futures Forums Cater to Companies that Can’t Gain Limelight Elsewhere, Co-founder Says

Kuldev Singh, MD (US), co-founder of Europe’s annual Ophthalmology Futures Forums (OFF), told Market Scope in October that he takes pride in the group’s record of giving “people with new ideas who ...

10/24/2023
DiagnosticDry EyeFundingNewsletter
Tilak Leads Latest Ophthalmic Fundraising with $10.6 Million Round
Tilak Leads Latest Ophthalmic Fundraising with $10.6 Million Round

France’s Tilak Healthcare led recent ophthalmic fundraising efforts with a $10.6 million funding round for its medical video games for chronic vision disorders. Financing announced in the past four...

10/13/2023
BreakingFundingIndustryLow Vision
Paris Court Opens Safeguard Proceedings, Similar to Bankruptcy, for Pixium Vision
Paris Court Opens Safeguard Proceedings, Similar to Bankruptcy, for Pixium Vision

France’s Pixium Vision reported Oct. 9 that the Commercial Court of Paris had opened safeguard proceedings—similar to bankruptcy protection—for the company, after Pixium said it might not be able t...

9/21/2023
CataractCornealDry EyeFundingGene TherapyNewsletterPharmaRetina
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue

Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...

9/21/2023
FundingNewsletterRetina
CIRM Grants $12.4 Million to Regenerative Patch Technologies to Advance RPE Implant
CIRM Grants $12.4 Million to Regenerative Patch Technologies to Advance RPE Implant

The California Institute for Regenerative Medicine (CIRM) announced July 27 that it had awarded a $12.4 million grant to Regenerative Patch Technologies (RPT) to support a Phase IIb clinical trial ...

9/1/2023
BreakingDealsFundingRetina
CIRM Grants $12.4 Million to Regenerative Patch Technologies to Advance RPE Implant 
CIRM Grants $12.4 Million to Regenerative Patch Technologies to Advance RPE Implant

The California Institute for Regenerative Medicine (CIRM) announced July 27 that it had awarded a $12.4 million grant to Regenerative Patch Technologies (RPT) to support a Phase IIb clinical trial ...

8/22/2023
CataractCornealDry EyeFundingGene TherapyIOLNewsletterPharmaRetinaSurgical
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C

Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....

8/10/2023
BreakingFundingGlaucomaPharmaStudy
NIH $2.5 Million Grant Funds Glaucoma Treatment Research at Missouri S&T
NIH $2.5 Million Grant Funds Glaucoma Treatment Research at Missouri S&T

The Missouri University of Science and Technology announced July 31 that one of its professors researching glaucoma treatments was awarded a grant from the National Institutes for Health that will ...

8/4/2023
BreakingDry EyeFunding
Tarsus Prices $100 Million Public Offering of Common Stock
Tarsus Prices $100 Million Public Offering of Common Stock

Tarsus Pharmaceuticals announced July 31 that it had commenced an underwritten public offering of $100 million in common stock. The Irvine, California, company said it would grant the underwriters ...

7/25/2023
DealsFundingNewsletter
Venture Capital and OUS Investments in Ophthalmology Bounce Back in Q2-2023
Venture Capital and OUS Investments in Ophthalmology Bounce Back in Q2-2023

Ophthalmic deals in Q2-2023 surpassed $6.9 billion and involved 24 transactions. This compares with $1.8 billion from 16 transactions in Q1-2023 and $1.7 billion from 23 transactions in Q2-2022. Pu...

7/25/2023
CornealFundingGlaucomaNewsletterRetina
NeuroGene Leads Latest Ophthalmic Fundraising with $95 Million Private Placement
NeuroGene Leads Latest Ophthalmic Fundraising with $95 Million Private Placement

Neurogene led recent ophthalmic fundraising efforts with a $95 million private placement, as it advances its pipeline, including a gene therapy candidate for Batten disease. Funding announced in th...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more